Skip to main content
Caplight Logo









VitroScan

VitroScan

Private
LeidenHealthcare & Life Scienceshttps://vitroscan.com/

Last Round

Health Holland

Grant

May 26, 2026

Total Funding Raised

$5.31M

Company Overview

VitroScan is a biotechnology company that provides a 3D micro-tumor testing platform designed to support precision treatment development for cancer patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

precision oncologyex vivo testingtumor organoidspredictive diagnostic assaydrug sensitivity testingpersonalized cancer therapy3D cell cultureclinical trial de-riskingcancer drug discoverypredictive analyticspatient-derived modelsorgan-on-a-chipbiotech service provider

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VitroScan Comparables

Compare VitroScan with similar companies based on industry and business-model similarity.

VitroScan comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xsphera Biosciences
89%
Xilis
87%
Apricot Therapeutics AG
86%

VitroScan Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Health Holland GrantMay 26, 2026
GrantApr 22, 2025
GrantDec 2, 2024
GrantSep 5, 2023
GrantAug 23, 2022
Grant
Aug 15, 2019

Key People

Founding team and executive leadership

Willemijn Vader

CEO

Executive Team

VitroScan Investors

Notable investors and investment history

VitroScan investors
InvestorRounds
KWF Dutch Cancer SocietyGrant
EIT HealthGrant
Eurostars SME programmeGrant
Libertatis Ergo HoldingSeed
medical:forge LeipzigGrant
Health~HollandHealth Holland Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 2, 2024

    $2M grant round led by Biotech Booster

  • Apr 11, 2019

    $901K round with Libertatis Ergo Holding and Pieter Geelen.

VitroScan Filings

Explore SEC and related filing metadata, where available.

VitroScan filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about VitroScan's valuation, stock price, and market status.

Is VitroScan a public or private company?

VitroScan is a private company.

What is the current stock price of VitroScan?

VitroScan is a private company with no public stock price. No recent secondary market data is available.

How much is VitroScan worth (valuation)?

Valuation information for VitroScan is not publicly available.

Can I buy VitroScan stock?

VitroScan shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was VitroScan's last funding round?

VitroScan's most recent funding round was Grant on April 22, 2025.

Who are the main investors in VitroScan?

Key investors in VitroScan include EIT Health, Libertatis Ergo Holding, medical:forge Leipzig.

Will VitroScan IPO soon?

No public IPO plans have been announced for VitroScan.

How can I track VitroScan secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VitroScan's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLeiden
Employee Range8
Year Founded2016
Last FundingMay 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?